

NewAmsterdam Pharma Company N.V.  
Gooimeer 2-35  
1411 DC Naarden  
The Netherlands

January 26, 2023

**Via EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-3561  
Attn: Cindy Polynice  
Joe McCann

**Re: NewAmsterdam Pharma Company N.V.  
Amendment No. 1 to Registration Statement on Form F-1  
Filed January 17, 2023  
File No. 333-268888**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Securities Act"), NewAmsterdam Pharma Company N.V. (the "Company") hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-1 (the "Registration Statement") be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on January 30, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.

We respectfully request that we be notified of such effectiveness by a telephone call to Kerry S. Burke of Covington & Burling LLP at (202) 662-5297 and that such effectiveness also be confirmed in writing.

Respectfully,

**NewAmsterdam Pharma Company N.V.**

By: /s/ Michael Davidson

Name: Michael Davidson

Title: Chief Executive Officer and Executive Director

cc: Kerry S. Burke, Covington & Burling LLP